<DOC>
	<DOCNO>NCT00805896</DOCNO>
	<brief_summary>Songyou Granule mixture 6 herb . Vitro vivo study show Songyou Granule inhibit HCC cell grow , HCC metastasis . Hypothesis study TACE plus Songyou Granule improve outcome patient advance hepatocellular carcinoma ( HCC ) compare TACE .</brief_summary>
	<brief_title>Songyou Granule Transarterial Chemoembolization Hepatocellular Carcinoma</brief_title>
	<detailed_description>Primary outcome Measures : To evaluate effect TACE plus Songyou Granule TACE plus placebo TTP Secondary Outcome Measures : - Overall survival ( OS ) - Progression Free Survival ( PFS ) - The overall response rate - Time symptomatic Progression - In exploratory manner relative TTP , TTSP , RR overall survival 2 study population - Overall response duration time objective response - Overall disease control rate - The safety , tolerability , adverse event profile two treatment regimen use trial Enrollment : 260 Study Start Date : January 2009 Study Completion Date : December 2010 Primary Completion Date : December 2010 ( Final data collection date primary outcome measure )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Adults patient ( ≥ 18 year age ) diagnosis HCC amenable surgical resection local ablative therapy Histological confirm HCC clinical/laboratory diagnosis HCC nodules large 2 cm typical vascular feature AFP &gt; 200 Patient must quantifiable disease limited liver Patients must least one tumor lesion meet follow criterion : The lesion accurately measure least one dimension accord RECIST criteria The lesion previously treat surgery , radiation therapy , radiofrequency ablation , percutaneous ethanol acetic acid injection , cryoablation . ECOG performance status ( PS ) &lt; 2 No prior target antiangiogenic therapy . Metronomic chemotherapy allow . At least 4 week since prior systemic chemotherapy No significant baseline liver dysfunction . Cirrhotic status ChildPugh class A B No significant renal impairment ( creatinine clearance &lt; 30 mL/minute ) patient dialysis The following laboratory parameter : Platelet count ≥ 50,000/µL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 2 mg/dL ASL AST ≤ 5 x upper limit normal Serum creatinine ≤ 1.5 x upper limit normal INR ≤ 1.5 PTT within normal limit Ability understand protocol agree sign write informed consent document Previous concurrent cancer distinct primary site histology HCC except cervical carcinoma situ , treat basalcell carcinoma skin , superficial bladder tumor ( Ta , Tis &amp; T1 ) , cancer curatively treat &gt; 3 year prior entry permit Renal failure require hemo peritoneal dialysis ChildPugh C hepatic impairment Patients clinically significant gastrointestinal bleeding within 30 day prior study entry Known central nervous system tumor include metastatic brain disease History organ allograft Substance abuse ( current ) , psychological , social condition may interfere patient 's participation study evaluation study result . Known suspect allergy investigational agent agent give association trial . Patients unable swallow oral medication . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within seven day prior start study drug . Both men woman enrol trial must use adequate barrier birth control measure course trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>